Small molecule modulators of Wnt/β-catenin signaling

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Wnt signal transduction pathway dysregulation is implicated in numerous prevalent diseases, notably cancer.
• Drug discovery for Wnt pathway modulators is challenged by limited targets and suitable drug candidates.
• Niclosamide, an FDA-approved anthelmintic, was previously identified to inhibit Wnt/β-catenin signaling via an unelucidated mechanism.

Purpose of the Study:

• To investigate the mechanism of Niclosamide's inhibition of Wnt signaling.
• To explore structure-activity relationships (SAR) of Niclosamide and related compounds.
• To identify the molecular target responsible for Niclosamide's Wnt pathway inhibitory effects.

Main Methods:

• Screening of structurally related anthelmintic agents for Wnt inhibition.
• Detailed analysis of Niclosamide's chemical structure and its impact on potency.
• Functional assays to assess Wnt/β-catenin signaling inhibition.

Main Results:

• Niclosamide's inhibition of Wnt signaling was found to be unique among tested related anthelmintics.
• The potency and functional outcome of Niclosamide's inhibition were sensitive to minor structural modifications.
• The specific molecular target of Niclosamide remains unidentified.

Conclusions:

• These findings underscore the need for continued efforts to identify Niclosamide's target in Wnt/β-catenin signaling.
• Understanding the target will facilitate the development of novel, potent, and selective Wnt pathway modulators.
• Such modulators hold promise for the treatment of various human diseases, including cancer.